December 12, 2016
Ipsen science boss, R&D Vice President Claude Bertrand leaves
French drugmaker Ipsen said on Monday that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will step down in January…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 12, 2016
Eli Lilly and AstraZeneca join forces to fight Alzheimer’s disease
Eli Lilly and AstraZeneca have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which…
December 12, 2016
Short: Sycomore Asset Management’s share of Biocartis trigers transparency act
Biocartis Group NV said on Monday, in accordance with the Belgian Transparency Act, that Sycomore Asset Management now holds 3.01% of the…
December 12, 2016
Mereo balance sheet strong, sufficient funds for clinical tests
Mereo BioPharma Group, a clinical stage, UK-based biopharmaceutical company focused on rare diseases, is looking to strengthen its rare and specialty disease…
December 12, 2016
Herantis gets funds for its Parkinson’s disease study
The research and innovation program of the European Union, Horizon 2020, has awarded a grant of approximately €6.0 million for…
December 12, 2016
Novartis combination against age-related vision loss fails tests
Novartis was denied bringing its eye drug combination of pegpleranib and Lucentis out of Phase III study for age-related vision…
December 9, 2016
Valneva to test its Lyme disease vaccine
Valneva said on Friday it will sent its Lyme disease vaccine candidate VLA15 to clinic. Phase I testing can begin…
December 9, 2016
Allergan dissapointed with PTAB’s reaction as Mylan petitions for IPR of Restasis patents
Allergan said on Thursday that it was disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that…
December 9, 2016
Alzheimer’s disease drug study disappoints Lilly
Eli Lilly has presented detailed results of its disappointing phase 3 Expedition3 trial at the 9th Clinical Trials on Alzheimer’s…
December 8, 2016
Horizon quits Friedreich’s ataxia treatment study
Horizon Pharma has announced that the Phase 3 trial, Steadfast (Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich’s Ataxia study), evaluating Actimmune (interferon gamma-1b) for…